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Abstract  
In autism spectrum disorders, many parents resort to alternative treatments and these are generally perceived as 
risk free. Among these, the most commonly used is the gluten-free casein-free diet. The objective of this work 
was to conduct a systematic review of studies published from 1970 to date related to the gluten-free casein-free 
diet in autism spectrum disorders patients. Few studies can be regarded as providing sound scientific evidence 
since they were blinded randomised controlled trials, and even these were based on small sample sizes, reducing 
their validity. We observed that the evidence on this topic is currently limited and weak. We recommend that it 
should be only used after the diagnosis of an intolerance or allergy to foods containing the allergens excluded in 
gluten-free casein-free diets. Future research should be based on this type of design, but with larger sample sizes. 
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Introduction 
Autism spectrum disorders are a clinically characterised by difficulties with reciprocal social interactions, verbal 
and non-verbal communication deficiencies and restricted, repetitive and stereotyped behaviors and interests1. 
According to a recent publication analysing 2008 data2, the prevalence has increased to 11.3 per 1000 people, 
and it is notably more common in men (ratio 4:1).  On the other hand, no significant differences have been 
reported as a function of socioeconomic level or cultures3. 
 
Gluten-free casein-free diet: background 
So far, there are no curative treatments for this disorder, and though there is some hope of advances4. In this 
context, many parents have turned to alternative treatments5,6,7  driven by the frustration and concern caused by 
the diagnosis rather than with sound justification, and this issue is compounded by the fact that the treatments are 
generally thought to be risk-free. These alternative treatments include the adoption of elimination diets, in 
particular the gluten-free casein-free diet8, the focus of this paper. 
In relation to this, the elimination of gluten implies the exclusion of all food items containing wheat, oats, barley 
or rye, that is, all flours, bread, rusks, pasta, pastries and other bakery products made with these cereals, while 
the elimination of casein means no intake of dairy products: milk, including breast milk, yogurt, cheese, butter, 
cream or ice cream, among others. 
On the other hand, in relation to autism spectrum disorders children, these diets involve significant changes to 
their routine and such changes may, in themselves, affect their eating behaviors9,10,11. Additionally, the adoption 
of elimination diets works against efforts to improve the social integration of such children, in that a personal 
diet is an isolating factor12. 
 
Opioid theory for autism spectrum disorders 
The most commonly cited theory to justify adoption of a gluten-free casein-free diet is related to 
neurotransmitters13 and concerns the release of peptides with an opioid activity in the intestines. After digestion, 
certain types of proteins could cross the intestinal mucosa intact14, if this were more permeable than normal, this 
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being the case when it is impaired by immunological factors or by lesions in the case of celiac disease. If these 
peptides, transported by the blood stream, were to cross the blood-brain barrier and reach the central nervous 
system in large quantities it would affect brain functioning15. The hydrolysis of proteins from cereals and milk 
would generate exogenous neuropeptides (exorphines) such as gluteomorphins from gluten and beta-
casomorphins from casein.  
It should, however, be highlighted that exorphins have a low affinity for opioid receptors and that in dietary 
proteins there are also amino acid sequences with antagonist activity on opioid receptors which, despite having 
been known of for many years, tend not to be considered in this context16.  
What is more, experiments have failed to find abnormally high concentrations of opioid peptides in either plasma 
or the nervous system of patients with autism spectrum disorders 17. As for urinary excretion, urinary opioid 
peptides have not been detected in people with autism spectrum disorders  using modern methods with great 
sensitivity and specificity (namely, mass spectrometry coupled with high-performance liquid 
chromatography)18,19,20. 
 
Prevalence 
     The adoption of gluten-free casein-free diet, as an alternative treatment, is a poorly studied phenomenon. In 
the literature, figures are highly variable, indicating that this approach is tried in 20 to 70% of cases. For 
instance, Harrington et al6  reported that 66% , Wong et al21  found that 30%,  Herndon et al22  reported 31.1%, 
Bandini et al23  indicated that 20.7%, Hall et al24  and Sharp et al25  reported rates of 30%.  
 
Behavior and Physiological Perspective 
The first author to establish an association between the frequency and severity of schizophrenia and the intake of 
foods containing gluten and dairy products was Dohan: their withdrawal improved symptoms and their 
reintroduction worsened them26,27. Subsequently, Panksepp28  suggested that the behavioral changes associated 
with autism were the result of an abnormal activation of the opioid system due to an excess of agonists in the 
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brain. It has been considered that gluten from cereal and casein from dairy products could be responsible, as they 
are a source of “exorphins”, peptides with opioid activity29-32. 
Considering publications since 1970, excluding theses or book chapters, we found relatively few original studies 
on elimination diets that analyse their impact on behavior in autism spectrum disorders.  Among these, 
demonstrated significant improvements in intervention vs. control groups, and Whiteley et al33  reported the 
appearance of a possible diet-related autism phenotype that seems to be emerging supportive of a positive dietary 
effect with slight improvement in certain groups with autism spectrum disorders. On the other hand, Sponheim12 
did not observe any improvement after introduction of the elimination diet, but rather behavioral regression due 
to stigmatisation. Elder et al34  and Seung et al35 , did not find any improvement in the behavior of participants in 
the intervention group.  
 Having discussed the questionable effectiveness of this nutritional intervention on cognitive-behavioral 
function, we will now assess its safety. Cornish11 did not find any significant nutritional differences between 
autism spectrum disorders children as a function of whether they were on the gluten-free casein-free diet, similar 
to the findings of Johnson et al36. On the other hand, Arnold et al37  observed a significantly lower concentration 
of amino acids, including tryptophan in children with autism spectrum disorders on gluten-free casein-free diets. 
Higher homocysteine levels have been observed in patients on a gluten-free diet long-term compared to typical 
development children, and this implies deficiencies in folates and vitamin B6, increasing cardiovascular risk in 
the medium and long term38-40. Mariani et al41  reported that patients on a gluten-free diet had high intakes of 
proteins and lipids but low intakes of carbohydrates, fibre, calcium and iron. In line with this, Marcason42,43 
warns about the risk of gluten-free diets resulting in deficient intake of both macro and micronutrients, the 
associated restrictions making it much more difficult to achieve a balanced diet than when a broader variety of 
foods are consumed. 
Similarly, a casein-free diet could result in calcium deficiency44-47. Aldamiz-Echevarria et al48  indicated that 
76% of patients on a casein free diet had a total lipid intake within the recommended range, but 85% had high 
ratios of ω6/ω3 and low plasma levels of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), a 
similar pattern being described by Schuchardt et al49 . Further, slower bone development was observed in autism 
spectrum disorders children on a casein free diet than among those without dietary restrictions50, while 
Neumayer et al51  demonstrated that children with autism spectrum disorders had a lower bone density than 
6 
 
controls. In this latter study, the total energy and macronutrient intakes did not differ significantly between 
groups, but the intakes of vitamin D and calcium were lower in children with autism spectrum disorders and this 
may be attributable to less consumption or even the elimination of milk and other dairy products.  
All the above justifies this systematic review of the studies published since 1970 concerning dietary restriction 
and its impact on autism spectrum disorders. Specifically, the objectives of this study were to determine, on the 
basis of the available scientific data: a) their apparent efficacy, and b) any possible associated metabolic risks. 
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Methods 
We conducted a systematic review of the medical literature related to gluten-free casein-free type diets. The date 
of the last search was 30 September 2013. We based our search on the Medline database, in accordance with the 
proposals of the Spanish National Health System In addition, we also consulted other databases (Cochrane 
Library, Scielo, ScienceDirect and Embase). For the searches, we used the following keywords: gluten-free, 
casein-free diet, autism, Autism Spectrum Disorders (ASDs) and review, with the corresponding Boolean 
operators. This paper complies with the methodological norms established for the publication of systematic 
reviews52,53 and the PRISMA recommendations54. 
We first retrieved systematic reviews and full original articles published from 1970 to 2013. These publications 
were then included in the analysis provided that: the participants, of any age, met the DSM-IV-TR criteria for 
autism spectrum disorders, that they were put on a diet excluding gluten, casein or both; and that the outcome 
variables were related to the potential biomedical or behavioral symptoms of autism spectrum disorders. We did 
not restrict the searches by language. On the other hand, studies in which the diet was not under supervision of 
the researchers and any which did not report on health outcomes were excluded. 
To guide the evaluation of the data in the papers retrieved, we defined levels of evidence, on the basis of their 
methodological quality in terms of the study design. We then established grades of recommendations for the 
planning of dietary guidelines for patients with autism spectrum disorders. For this classification of the evidence 
and recommendations, we employed an instrument proposed by the Scottish Intercollegiate Guidelines 
Network55. The scale proposes that two characteristics of the source be used for assessing the quality of the 
scientific evidence provided (level of evidence): the study design and the risk of bias. Numbers from 1 to 4 are 
used to rate the study design, while signs (++, + and -) indicate the assessed risk of bias, according to the degree 
of fulfillment of key criteria related to this potential risk (Table 1). Based on this assessment of the quality of the 
scientific evidence in the source, grades are used (Table 2) to classify the strength of associated 
recommendations (A,B,C,D). 
In addition to the aforementioned system of levels, we considered the following features, as applicable, to assess 
the level of evidence provided by the selected articles: (A) Degree of homogeneity of the group studied (as 
determined by definitions and criteria applied); (B) use of a control group and the appropriateness of the 
selection; (C) type of experimental design (randomized or not); (D) knowledge of the intervention by patients, 
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relatives and other observers (open, simple or double blind trial); (E) nature of the dietary regimen (level of 
strictness) and degree of adherence; (F) selection of assessment criteria, including the instruments used 
(questionnaires, scales, etc.) for assessing changes in patient status under the treatment; and (G) the presence of 
confounding factors including any types of pharmacological treatments provided, or the use of one or more 
intervention procedures that could affect the assessment criteria selected. 
For evaluating and synthesizing the scientific evidence, we also considered the internal validity of the studies, 
whether there was statistical significance and the accuracy of the results, as well as their clinical relevance. We 
then characterized the recommendations on the basis of the quantity, generality, and clinical relevance of the 
results as well as the quality of the scientific evidence.  
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Results 
The studies retrieved were analysed in terms of the following characteristics, as applicable: sample size, study 
design, assessment and intervention criteria, and the results, as well as the level of evidence and the grade of 
recommendation. Tables 3 and 4 summarise the characteristics of the studies the results of which have been 
referred to above. 
 
Effectiveness 
Scientific literature on this topic is relatively scarce. Among the studies that refer to the effectiveness, only 
four12,34,35,56  may be considered to provide high scientific evidence. The studies of  Harland57 and Hyman58  not 
yet completed. Millward59  and Mulloy60,61  in their papers present systematic reviews, evaluated with the highest 
level of evidence and grade of recommendation. Notably, in our analysis, the studies that reported positive 
results were classified with the lowest levels of evidence, while the rest reported negative results with regards 
this type of dietary intervention. None of the studies identified provided conclusive evidence because they had 
poor validity (Table 3). 
 
Safety 
There are similarly few publications addressing the safety of the gluten-free casein-free diet. Among those 
identified, the studies of Konstantynowicz et al46  and Hediger et al50 provide the highest level of evidence. 
Nevertheless, in the results found there was a certain degree of consensus on the risks that could be associated 
with following this type of restriction diet (Table 4). 
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Discussion 
     Data in the literature in this field is very limited both in quantity and quality. To assess the effectiveness and 
safety of the gluten-free casein-free elimination diet, we considered both behavioral (verbal and non-verbal 
communication, stereotypy and disruptive behavior) and biomedical variables (e.g. urinary peptides, gliadin and 
endomysial antibodies, as well as other laboratory data and nutrient intake). Methodological limitations 
identified were associated with a range of factors: the lack of a control group and/or clear definitions of inclusion 
criteria, very small sample sizes and analysis being based on single individuals or anecdotal information, groups 
being heterogeneous in terms of age, failure to control for phenotypic variability between individuals, and 
interventions being of variable duration and generally short, as well as lack of pre-/post-intervention 
comparisons. There was also a risk of bias in data on the behavioral variables attributable to memories of parents 
and other caregivers being distorted over time and that their perception of changes in the behavior of participants 
may be subjectively influenced by the fact of being included in non-blinded trials. Similarly, a placebo effect 
may have had an impact on results. Lastly, alternative explanations were not always considered, such as the of 
risk of confounding bias, in particular, it being possible that behavioral improvements were due to ongoing 
development and behavioral therapy given, rather than to gluten-free casein-free diets per se. Finally, it should 
be noted that the literature search may not have identified all the relevant publications, and the review itself may 
be sensitive to information bias. 
 
Recommendations 
On the basis of this review, we conclude that the evidence to support gluten-free casein-free diets is limited and 
weak, such dietary restrictions being associated with social rejection, stigmatisation, deficits in socialisation and 
integration, and a misuse of resources, as well as potential adverse biomedical effects. Hence, we advise against 
resorting to elimination diets in an attempt to treat autism spectrum disorders. Specifically, until there is 
conclusive evidence of the benefits of gluten-free casein-free diets in autism spectrum disorders, they should 
only be introduced after the diagnosis of an intolerance or allergy to allergens in the foods that would be 
eliminated in such a diet. Similarly, the results retrieved do not support the opioid theory. 
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Implications for the practice 
As a final recommendation, we underline that, when used, elimination diets must be at least as closely monitored 
as other types of intervention, to allow doctors, parents, and other caregivers to optimise treatments and hence 
health outcomes for these children. On the other hand, a diet-related specific end phenotype may be a target for 
future research and even a marker for the gluten-free casein-free dietary intervention. 
Based on the results of this review, future research should be focussed on blinded randomised controlled trials, 
and include larger samples sizes. 
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Table 1.  Levels of evidence 
 LE Characteristics 
1 1++  high-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias
 1+  well-conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias. 
 1-  well-conducted meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias. 
2 2++  high-quality systematic reviews of case-control or cohort or studies. 
 2+ 
 high-quality case-control or cohort studies with a very low risk of confounding, bias, or 
chance and a high probability that the relationship is casual. 
 2- 
well-conducted case control or cohort studies with a low risk of confounding, bias, or chance 
and a moderate  probability that the relationship is casual. 
3  non-analytic studies, e.g. case reports, case series. 
4   expert opinion. 
 
Abbreviations: SIGN, Scottish Intercollegiate Guidelines Network (2008); LE, levels of evidence; RCT: 
randomised and controlled trials. 
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Table 2. Grades of recommendation 
 GR Definition 
 A 
at least one meta-analysis, systematic review, or RCT rated as 1++, and directly 
applicable to the target population; or a systematic review of RCTs or a body of 
evidence consisting principally of studies rated as 1+, directly applicable to the target 
population, and demonstrating overall consistency of results 
 
 B 
a body of evidence including studies rated as 2++, directly applicable to the target 
population, and demonstrating overall consistency of results; orextrapolated evidence 
from studies rated as 1++, or 1+ 
 
 C 
a body of evidence including studies rated as 2+,directly applicable to the target 
population, and demonstrating overall consistency of results; or Extrapolated evidence 
from studies rated as 2++ 
 
  D 
evidence level 3 or 4; or                                                                                                       
extrapolated evidence from studies rated as 2+ 
 
Abbreviations: SIGN, Scottish Intercollegiate Guidelines Network (2008). GR, Grade of Recommendation; 
RCT: randomised and controlled trials. 
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Table 3. Studies considering the effectiveness of the gluten-free casein-free diet. 
Author N Design Assessment criteria Results LE GR 
Goodwin et al, 
197162 
 Cases: 15 
children with 
ASDs 
Age: 6-13 years 
old.                       
Controls: 14  
Siblings. 1-13 
years.   
Cross over 
intervention 
with gluten load 
test after GF 
diet 
Randomised.      
Open-label.        
Experimental. 
Blood biochemistry.  
EEG. Behavioral. 
Correlation 
between autism 
and malabsorption, 
and between gluten 
sensitivity and 
cognitive 
impairment  
 
3 D 
Bird et al,       
197763 
9-year-old child 
with ASD. No 
controls 
Case report.     
GFCF diet. 
Experimental. 
Behavioral. Diet does not 
affect behavior  3 D 
O´Bannion et al, 
197864 
One child with 
ASD. No controls   
Descriptive.       
Case report. 
Behavioral.  
Dietary restriction  
Wheat, maize, 
tomatoes, sugar, 
mushrooms and 
dairy products 
cause behavioral 
problems in the 
child                         
3 D 
Mc Carthy et al, 
197965 
8 patients with 
ASD, unknown 
age.                         
No healthy 
controls  
Open label. 
Gluten load 
after GF diet  
Clinical picture and 
intestinal biopsy  
No abnormal 
histological 
findings in the 
intestine.  
No association 
between autism 
and celiac disease 
2-   
Reichelt et al, 
199066 
15 patients with 
ASDs  
3-17 years old.        
Open label.          
urinary peptide 
levels, 
GFCF/GF/CF, 
cohort study.   
Peptiduria.  
Parent and 
caregivers 
questionnaire with 
retrospective 
comparison  
Behavioral 
improvement after 
the treatment in 
more than 50% of 
children  
3 D 
Knivsberg et al, 
199029 
15 patients with 
ASD, 6-14 years 
if age,                      
No healthy 
control group. 
Open label.          
urinary peptide 
levels, GF/CF, 
cohort study.  
Parent and caregiver 
reports.  
Standardised 
assessment 
questionnaires 
Early improvement 
(first 6 months), 
less evident after 1 
year   
3 D 
Sponheim,       
199112 
4 adults and 3 
children with 
ASDs.   6-month 
GF diet 
Experimental.   
Randomised.       
Double blind 
(gluten free or 
placebo 1 y).  
Cohorts. 
Parent and caregiver 
reports.  
Standardised 
assessment 
questionnaires 
 
No behavioral 
improvement  
2++ B 
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Lucarelli et al, 
199567 
36 patients with 
ASDs, 8-13 years 
old; 
Controls: 20 
children without 
ASDs for the 
caseinload test; 
2-month CF diet 
Open label 
before and after 
dietary 
restriction. 
Casein load 
test: Double 
blind, placebo-
controlled 
cohort study  
Standardised 
assessment 
questionnaire. 
Measurement of Ig 
levels. 
After the dietary 
restriction, 
decrease in the 
specific Ig levels.  
Behavioral 
improvement.  
Casein load test 
results not 
conclusive 
2-   
 
Abbreviations: ASD, autism spectrum disorder; GR, Grade of Recommendation; LE, level of evidence; GF, 
gluten free; CF, casein free; GFCF, gluten-free casein-free. 
The studies classified as 1– or 2– were not used in the recommendation process given the high risk of bias 
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Table 3. Studies considering the effectiveness of the gluten-free casein-free diet (cont.) 
 
Author N Design 
Assessment 
criteria 
Results LE GR 
Knivsberg et 
al, 199568 
Continuation of 
the previous 
study                      
cf. Knivsberg et 
al.  (1990). 
Experimental. Open 
label, urinary peptide 
levels, GF/CF, cohort 
study.  
Peptiduria.  
Parent and 
caregiver 
reports, 
Standardised 
assessment 
questionnaires   
No clear 
improvement after 
one year   
3 D 
Adams et al,   
199769 
One boy and one 
girl with ASDs;     
Both 3 years old 
Series of cases. 
 1) Very high doses of 
Mg+B6.                         
2) GFCF for 2 years. 
Parents report   Anecdotal 
improvement of 
the general 
behavior 
3 D 
Knivsberg et 
al, 199970 
 Girl with an 
ASD, 7 years old 
Case report 
GF for 2 years, 
Experimental. 
Parents report. 
Standardised 
assessment 
questionnaires  
Behavioral 
improvement in 
communication 
and socializing   
3 D 
Whiteley et al, 
19999 
Cases: 5 children 
with ASDs and 9 
children with 
autism.  
No randomised 
controls: 6 
children 
all diagnosed 
with autism, 
formed a control 
group of children 
not 
involved with 
any dietary 
intervention 
GF>6 months.   
GF diet for 5 months. 
Experimental.    
Cohort study 
Peptiduria. 
Parents report. 
Standardised 
assessment 
questionnaires 
 Behavioral 
improvement 
2-   
Cade et al,        
200010 
150 children with 
ASDs aged 
between 3.5-16 
years old.  
No healthy 
controls. 
Open label. 
Gluten load test after 
GF diet 
Experimental. 
Behavioral. 
Peptiduria. 
Improvement of 
the autistic signs 
and symptoms   
2-   
Knivsberg et 
al, 200271 
Cases: Ten 
children with 
ASDs, GFCF diet 
for a year. 
Controls: 10 
children with 
ASDs with 
normal diet.  
Both groups with 
a mean age of 7.5 
Randomised. 
Simple blind.  
GFCF diet for a year     
Experimental. 
Parents and 
caregiver report. 
Standardised 
assessment 
questionnaires 
Behavioral 
improvement in 
communication 
and socializing   
2+ C 
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years. 
Elder et al,    
200634 
15 people with 
ASDs.  
Aged 2-16 years 
old.  
GFCF diet for 12 
weeks.  
No healthy 
controls 
Randomised, 
retrospective, double 
blind, cross-over 
(RCT), 6 week under 
normal and GFCF 
diet, alternately  
 
  
Parents report. 
Standardised 
assessment 
questionnaires. 
Urinary peptide 
levels 
No statistically 
significant 
differences were 
observed   
2++ B 
Irvin 200672 One boy with an 
ASD,  
12 years old  
Case report,  
GFCF for 4 days 
Direct 
observation of 
the level of 
aggression and 
destructive 
behavior 
No behavioral 
change   
3 D 
 
The studies classified as 1– or 2– were not used in the recommendation process given the high risk of bias. 
Abbreviations: ASD, autism spectrum disorder; GR, Grade of Recommendation; LE, level of evidence; GF, 
gluten free; CF, casein free; GFCF, gluten-free casein-free. 
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Table 3. Studies considering the effectiveness of the gluten-free casein-free diet (cont.) 
 
Author N Design Assessment criteria Result LE GR 
Patel et Curtis, 
200773 
10 children with 
ASDs and ADHD 
aged between 4-
10 years old.  
No healthy 
controls  
Open label, 
Experimental. 
Children received an 
integrated treatment 
based on nutritional 
(GFCF) and 
environmental 
changes, plus the 
chelating agents, for 
3-6 months, as well as 
the usual behavioural 
therapy and 
physiotherapy. 
Behavioral 
assessment by 
physicians/parents/ 
teachers. 
Urinary heavy 
metals. 
Lower urinary 
concentration of 
heavy metals. 
Parents report a 
behavioral 
improvement 
3 D 
Seung et al,   
200735 
13 children with 
ASDs; 
2-16 years old.  
No healthy 
controls.  
Retrospective, 
randomised, double 
blind, cross over 
study. Six weeks on a 
normal and GFCF 
diet, alternatively. 
Video recording, 
Assessment of 
verbal and non-
verbal 
communication 
No statistically 
significant 
differences were 
observed  
2++ B 
Millward et al, 
200859 
  Systematic review    There is no 
empirical 
evidence base for 
recommending 
the GFCF diet. 
1+ A 
Hyman et al,       
201056 
30 children with 
ASDs; 
30-45 months  
Experimental. 
Double blind. 
Cross over. 
Randomised, 
controlled (RCT),  
18 weeks under GFCF 
and normal diet 
alternately. 
Behavioral 
assessment  
No significant 
differences in the 
preliminary 
results (2010).  
No empirical 
evidence to 
recommend the 
GFCF diet.   
1+ A 
Mulloy et al,       
201060 
  Systematic review   No empirical 
evidence to 
recommend the 
GFCF diet  
1+ A 
Whiteley et al, 
201074 
72 children with 
ASDs.  
No healthy 
controls.  
Single blind, 
randomised, clinical 
trial. Grouped by 
ages, stratified.  
Conducted in 2 
phases. 
Standardised 
assessment 
questionnaires   
Peptiduria. 
Significant 
improvement in 
some ASD 
subgroups  
2+  C 
Mulloy et al,       
201161 
  Systematic review.   Confirmation of 
the conclusions 
reached by 
Whiteley P et al. 
(2010) 
1+ A 
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The studies classified as 1- and 2- were not used for establishing the recommendations given the high risk of 
bias.  
Abbreviations: GFCF, Gluten-free casein-free diet; GF, gluten free diet; CF, casein-free diet; ASD, Autism 
spectrum disorder; ADHD, Attention-deficit/hyperactivity disorder;  RCT, randomised controlled trial; LE, level 
of evidence; GR, Grade of recommendation; AA: amino acids.  
  
 
 
 
 
 
 
Harland  201257 In the recruitment 
phase, estimated 
number patients 
with ASDs 30; 
aged between 2-
17 years old.   
Experimental, double 
blind, cross over, 
randomised, 
controlled (RCT),  
18 weeks on GFCF 
and normal diet 
alternately. 
Behavioral 
assessment 
(activity, sleep, 
behaviors related 
to the ASD); Stool 
pattern, nutrition 
Not yet complete _ _ 
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Table 4. Studies considering the safety of the gluten-free casein-free diet. 
 
Author N Design Assessment criteria Result  LE GR 
Cornish et al,   
200211 
Cases: 8 children with 
ASDs, 3-16 years old; 
GFCF diet.               
Controls: 29 children 
with ASDs; 3-16 years 
old with no dietary 
restrictions    
Retrospective,  
Case-control 
3-day food diary   No differences 
observed for energy, 
macro and 
micronutrients   2-   
Black et al,  200244 Cases: 50 children who 
refuse milk (CF), 
controls 200 children 
who drink milk. Age 
range in both groups: 3-
10 years old  
Observational 
Cross-
sectional. 
4-day food diary.  
Food frequency 
questionnaire. 
Measurement of 
bone density 
Lower intake of 
calcium,  
Stature and bone 
density associated 
with CF diet 
 
2-   
Arnold et al, 
200337 
Cases: 36 children with 
ASDs, 26 with normal 
diet, 10 with GFCF diet. 
Controls: 24 without 
ASD                      Both 
groups under 5 years of 
age   
Observational. 
Cross-
sectional. 
Blood analysis Significant 
deficiency in AA 
(mainly tryptophan) 
associated with 
ASDs compared to 
controls, more 
pronounced on a 
GFCF diet    
2+ C 
Monti et al,     
200745 
One 8-year-old child  Case report Dairy product 
elimination diet. 
Lower bone density  
3 D 
Konstantynowicz  
et al, 200746 
Cases: 91 children with 
fractures. Controls: 273 
children without 
fractures.  
Age range: 2.5 to 20 
years old. 
Observational 
Grouped by 
age and sex.     
Randomised.    
Case-control. 
24-hour recall.  
Bone density   
Lower calcium 
intake and bone 
density in children 
with restriction of 
dairy products.   
Weak association 
between fractures 
and milk 
consumption   
2++ B 
Hediger et al, 
200850 
75 children with ASDs 
on a CF diet.  
No controls                 
Observational. 
Cross-
sectional. 
Cortical bone 
density 
Reduced 
2++ B 
Johnson et al,   
201136 
22 children with ASDs 
aged 3-5 years old. 
Cases: 8 children on a 
GFCF diet for 3 months. 
Controls: 14 children 
with no dietary 
restrictions 
Prospective, 
randomized, 
open-label 
cohort trial 
24-h recall No significant 
differences for 
proteins, lipids, 
carbohydrates, 
calcium and iron  
2-   
Neumayer et al, 
201251 
Cases: 18 children with 
ASD 
Controls: 19 typically 
developing children 
Age range in both 
Observational.   
Case-control. 
Bone mineral 
density. Analysis 
of blood and 
saliva;  
Physical exercise; 
Lower bone density. 
Lower physical 
activity. Lower 
intake of lactose, 
vitamin D, increase 
2+  C 
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groups 8-14 years 3-day food diary.  of salivary cortisol  
 
The studies classified as 1- and 2- were not used for establishing the recommendations given their high risk of 
bias.  
Abbreviations: GFCF. Gluten-free casein-free diet; GF: gluten free diet; CF: casein-free diet; ASD: Autism 
spectrum disorder; FFQ: Food frequency questionnaires; RCT: randomised clinical trial; LE: level of evidence; 
GR Grade of recommendation; and AA: amino acids.  
 
 
  
